Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | ADK | P55263 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25949266 | 1.00 | PDPK1 (0.37) | PDPK1GPR119JAK3ADKACACB | |
| SCHEMBL23892341 | 0.92 | PDPK1 (0.36) | PDPK1GPR119JAK3ADKPRMT5 | |
| SCHEMBL22002066 | 0.92 | PDPK1 (0.36) | PDPK1GPR119JAK3ADKPRMT5 | |
| SCHEMBL23892580 | 0.92 | GPR119 (0.33) | GPR119JAK3ADKACACBPRMT5 | |
| SCHEMBL18571923 | 0.85 | PDPK1 (0.40) | PDPK1GPR119JAK3 | |
| SCHEMBL18572228 | 0.85 | PDPK1 (0.40) | PDPK1GPR119JAK3 | |
| SCHEMBL25949326 | 0.83 | GPR119 (0.33) | GPR119JAK3ADKMETTL3JAK1 | |
| SCHEMBL25948966 | 0.81 | ABL1 (0.37) | PDPK1GPR119JAK3 | |
| SCHEMBL23892335 | 0.81 | ABL1 (0.37) | PDPK1GPR119JAK3 | |
| SCHEMBL22682987 | 0.79 | PDPK1 (0.32) | PDPK1GPR119PRMT5WDR77JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2020-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10653711-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | PDPK1 1687/4885GPR119 1894/4885JAK3 3018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.